Member Info for mowzerrocks

thanks luddite - I hadn't checked and forget that changed!

I think that is the problem here - the price has been affected by more wide spread lockdowns. So the problem with the rights is that it stops you from reacting to the market movements.

and also don't forget that stamp duty is not applicable on share rights issue, but is on the purchase of new shares.

And I think this is the key point from the message I got from HL:
However, in order to secure your application we are requesting that you make 88p available for each share you wish to buy – this isn’t the amount you’ll be charged but is an amount which should ensure you have enough cash after allowing for exchange rate movements. In the unlikely event that 88p is not sufficient we’ll contact you again.
So chances are the 88p is very much an overestimate.

* current market rates for rights

So at the current market rights for rights - it would be better to sell and and buy on the market. But it all hinges on what the conversion rate will be - 88p isn't fixed. It could be less dependent on brokers' conversion fees. Is that right?

I would have thought one with lower false negatives would be better before you boarded and the yes some sewage testing... obviously you don’t want masses of false positives clogging labs for mass testing but for entrance to confined spaces then perhaps the other way is better. just thinking out loud.

Just thought I would start a new thread that might be interesting. Has anyone submitted questions yet? I was thinking of asking about feasibility of having different tests for different testing situations - eg mass testing versus cruise ship where the S&S is tailored.

So the buy/sell is just worked out from the spread - so it isn’t necessarily correct ... or Richob do you mean the order book has more buy orders than sell orders?

that is their antibody test. Look at Hants post 3rd September. Subject Message from Sir Al

PL great summary of Boris - and something we agree on! He is completely incoherent most of the time. And JD has made a great point - our goal as shareholders is for the SP to rocket... however Boris’s goal is to achieve his target of 10m pd testing. The clinical validations will trigger a major rerate for us but Boris isn’t going to get a rerate until the tests are rolling off the conveyor belts and being pushed through letterboxes. There will be a period between clinical validation and all the right rubber stamps and distribution and usage. Could even be over a period of weeks and months. That is why production capacity is so critical as per the RNS. If Boris says we have it and it isn’t on doorsteps with 1-2 weeks he is toast. If he says we are on the brink but it is some way off - I take it to mean it is a huge part of Moonshot and he is buying time to stop himself getting burnt over delays. He wouldn’t mention it if the science wasn’t good and it wasn’t going to be a part of moonshot.

Hants post (thank you again and hope you don't mind me reposting as it can be difficult to dig through weeks of posts) -

RE: Medusa enquiry and email from Sir Al03 Sep 2020 10:35
PART 2:

I sent an email to Avacta last night expressing my concerns at Medusa’s sales literature. To my surprise I received an email back from Sir Al himself just after 8am this morning. I’m not going to copy and paste his email onto a public BB as I don’t believe that’s a fair thing to do. Here’s a summary in MY OWN WORDS but without any of the stated information altered.
____

There are many IgM//Igm tests already on the market and these antibodies don’t appear until at least a week into the infection. In a sense, it’s true that an antibody test can detect current infection but what everybody wants is a test which can identify the infectious people.

The infectious time period is around 2 days before symptoms appear, up to approximately 7 days at which point the viral load begins to fall. Therefore, by the time antibodies are made you’re mostly through the infectious/most infectious time period.

Governments are wanting to move towards widespread weekly testing to find the people who are most infectious (remember these words from the recent RNS, I know some people picked up on it and took it as a negative). This is what Governments are asking for and this is what a lateral flow antigen test can do, unlike centralised testing such as PCR.
___

It was a really great response from Sir Al. He did not pass comment as to whether he thought Medusa’s advertising was misleading, but nor would I expect him to. My hope is that he will contact them and when the website is updated (apparently that will be this week), it won’t include claims that their anti-body test can detect current infection as that’s somewhat misleading.

With all the bad articles on Boohoo lately, if there was an outbreak in a workplace after testing with their products had been completed and returned negative because they were the wrong type of test… can you imagine the newspaper stories! It would not be good.

PL - much improvement on yesterday - well done! ;) Seriously - I hope you got some sleep after all that. I agree it is annoying that multiple posters (or even the same person) is asking the same question when the answers were already provided this morning. However, with all the posts it CAN get lost, so for the sake of PR, just repost the good stuff... doesn't hurt to have hants post summarising an email from Al - I will repost it again.

There is a lot of anxiety about other tests. We have said this before, we come out with a good test (which all RNS's point to) then they will be snapped up. The Market is HUGE - there is room for other tests. Plenty of room. I appreciate when you have invested a lot of money, competition is a concern, but in this instance the market is the whole bl**dy world... you can't get bigger than that. In terms of PR, most of the competition have had some publicity and then other stuff comes out that down plays it. I'd rather Avacta have all their i's and t's dotted and more manufacturing partners signed up. That is the proof I need right now.

I don’t think we know exactly what the hold up is- Hants has another post where I believe sir Al says they are pushing their parters as hard as they can ... I would say that
1. It is critical they get the S&s right for the market they are targeting. There is a huge amount of info on the net about establishing s&s. Obviously moonshot has a huge market so prevalence will have an impact on s&s.

2. There could be a lot of NDA’s in place - a bit speculative but I’d be surprised if not having an impact on news flow
3. I would argue that the manufacturing RNS’s are mor important at present as capacity is going to be the biggest issue after s&s is established .

Hants post -

RE: Medusa enquiry and email from Sir Al03 Sep 2020 10:35
PART 2:

I sent an email to Avacta last night expressing my concerns at Medusa’s sales literature. To my surprise I received an email back from Sir Al himself just after 8am this morning. I’m not going to copy and paste his email onto a public BB as I don’t believe that’s a fair thing to do. Here’s a summary in MY OWN WORDS but without any of the stated information altered.
____

There are many IgM//Igm tests already on the market and these antibodies don’t appear until at least a week into the infection. In a sense, it’s true that an antibody test can detect current infection but what everybody wants is a test which can identify the infectious people.

The infectious time period is around 2 days before symptoms appear, up to approximately 7 days at which point the viral load begins to fall. Therefore, by the time antibodies are made you’re mostly through the infectious/most infectious time period.

Governments are wanting to move towards widespread weekly testing to find the people who are most infectious (remember these words from the recent RNS, I know some people picked up on it and took it as a negative). This is what Governments are asking for and this is what a lateral flow antigen test can do, unlike centralised testing such as PCR.
___

It was a really great response from Sir Al. He did not pass comment as to whether he thought Medusa’s advertising was misleading, but nor would I expect him to. My hope is that he will contact them and when the website is updated (apparently that will be this week), it won’t include claims that their anti-body test can detect current infection as that’s somewhat misleading.

With all the bad articles on Boohoo lately, if there was an outbreak in a workplace after testing with their products had been completed and returned negative because they were the wrong type of test… can you imagine the newspaper stories! It would not be good.

Hi Agent B - good question and Hants emailed Avacta and got a reply from Sir Al himself. The problem with detecting it with an antibody test is that it won’t detect the most infectious who haven’t reached that stage of the disease yet - so whilst not totally useless it won’t stop the spread from those not displaying symptoms yet. I think Hants post was about 10 days ago...

PL - you see the everything as a deramp that isn’t a ramp. That poster I was replying to was on here all weekend clearly deramping without real arguments or information . You get a poster like this Dave - he might be or he might not be deramping... he hasn’t even actually attacked Avacta directly. Remember the chap who lost most of his pension and was going all in on Avacta? You attacked him as a deramper too when he asked for some reassurance.... Naive yes he was... as is possibly Dave... maybe instead of going for the choke hold as soon as someone steps into the ring , stand back and gauge the right punch - not everything needs the heavy handed approach like tonight. You are a very frequent poster and you need to think a bit more about the PR aspect of doing so as a shareholder. You can either take that in the spirit it is intended or go through my posting history to try to attack me. I’m going to get some sleep. Good Night.

If you can’t see it when you are cutting your nose off to spite your face then perhaps just get out of the ring... your bleeding all over my investments and it somewhat ****es me off.

Doesn’t anyone here see the bad karma here? If I was a new investor reading these boards for some background - I could easily be put off by these kinds over way over done attacks on what is at worst a very light deramp.... It is seriously detracting from a what is a potentially an extraordinary company on the verge of creating a product the world desperately needs right now. Think about it ... and try to detract from potential deramps in a less aggressive and more mature manner. There is so much evidence and research done here that it is more than enough to fight back without lowering the board to gutter type insults. I say this as a heavily invested individual in AVCT who would like all media including BB’s to portray a positive image of the company. Thank You.